A novel
panTB Regimen
targeting both 
host and microbe

About panTB-HM

Tuberculosis is a leading global cause of morbidity and mortality. Even if cured, most patients are left with permanent lung damage that impairs lung function and shortens long-term survival. These concerns are increased many-fold in rifampin-resistant (RIF-R) TB, in which cure is less likely, and long-term outcomes are more profoundly affected. This project will develop the first regimen meeting WHO criteria for a pan-TB indication, ie, without requiring knowledge of RIF susceptibility. The regimen will combine sutezolid (a linezolid analog with a superior therapeutic index and safety profile in phase 1 and 2 trials) with the approved anti-TB drugs bedaquiline and pretomanid. This phase 2c trial will test sutezolid at 2 dose levels to optimize its efficacy and safety. It will also test whether the addition of N-acetylcysteine (NAC), a re-purposed host-directed WHO essential medicine, can protect the lung and liver against oxidative damage, preserve lung function, and accelerate the eradication of MTB infection by replenishing glutathione (GSH). Our modelling indicates this new regimen (SBPN) can be a highly effective intervention, preventing deaths due to treatment failure in patients with RIF-R-TB, and recovering years of life otherwise lost post-TB in all patients by preserving lung function. The project will be conducted by a consortium of public, non-profit, and private interests that bring unique knowledge, expertise, and capabilities.

panTB-HM is a 60-month clinical which started in October 2020 and will run until September 2025


No. 38


December 2023


September 2025

This Project (RIA2019AMR-2647) is part of the EDCTP2 Programme supported by the European Union


The Aurum Institute
Ludwig-Maximilians-Universitaet Muenchen
National Institute for Medical Reasearch
Instituto Nacional de Saude


PanTB-HM Clinical Trial Begins Recruitment in South Africa

The panTB-HM clinical trial has begun patient recruitment in South Africa, with first patient dosed on 28 July 2023. This trial is a historic milestone in the quest to revolutionise tuberculosis (TB) treatment and improve outcomes for all TB patients. The panTB-HM trial addresses the World Health Organisation (WHO) target profile for new TB regimens […]

Sutezolid and Tablets are now available

SUTEZOLID AND TABLETS ARE NOW AVAILABLE We are happy to announce that the manufacturing of Sutezolid API and tablets for this study is now complete. Aurum and Sequella worked with the TB Alliance for the trial's Chemistry, Manufacturing and Control (CMC) work package. We would like to thank Professor Robert Wallis (Aurum), Dr Carol Nacy [...]

Regimen could be the first to meet WHO criteria

REGIMEN COULD BE THE FIRST TO MEET WHO CRITERIA The regimen we are proposing could be the first to meet the WHO criteria below for a pan-TB indication, being fully comprised of new agents unaffected by current resistance.   Minimal Optimal Purpose Potential go/no-go decision point. Needed to achieve greater global impact. Indication 1st-line treatment [...]

Reducing TB Treatment to four months

REDUCING TB TREATMENT TO FOUR MONTHSOur trial, panTB-HM, responds to the Project to Accelerate New Treatments for Tuberculosis (PAN-TB). PAN-TB is a consortium of philanthropists seeking to accelerate the development of novel, shorter Tuberculosis treatments which are simpler to use and have better tolerability. panTB-HM, a phase 2c trial, will test Sutezolid at 2 dose [...]

Loading posts...
Sort Gallery

Verified by MonsterInsights